Evidence map›Paper›PMID 30254608›Full record

ReviewFrontiers in endocrinology2018

Cholesterol as an Endogenous ERRα Agonist: A New Perspective to Cancer Treatment.

Ivan Casaburi, Adele Chimento, Arianna De Luca, Marta Nocito, Sara Sculco, Paola Avena, Francesca Trotta, Vittoria Rago, Rosa Sirianni, Vincenzo Pezzi

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in endocrinology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 51 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Discovery of a Novel Class of ERRα Agonists.ACS medicinal chemistry letters · 2021
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Ivan CasaburiDepartment of Pharmacy and Health and Nutritional Science, University of Calabria, Cosenza, Italy.
Adele ChimentoDepartment of Pharmacy and Health and Nutritional Science, University of Calabria, Cosenza, Italy.
Arianna De LucaDepartment of Pharmacy and Health and Nutritional Science, University of Calabria, Cosenza, Italy.
Marta NocitoDepartment of Pharmacy and Health and Nutritional Science, University of Calabria, Cosenza, Italy.
Sara SculcoDepartment of Pharmacy and Health and Nutritional Science, University of Calabria, Cosenza, Italy.
Paola AvenaDepartment of Pharmacy and Health and Nutritional Science, University of Calabria, Cosenza, Italy.
Francesca TrottaDepartment of Pharmacy and Health and Nutritional Science, University of Calabria, Cosenza, Italy.
Vittoria RagoDepartment of Pharmacy and Health and Nutritional Science, University of Calabria, Cosenza, Italy.
Rosa SirianniDepartment of Pharmacy and Health and Nutritional Science, University of Calabria, Cosenza, Italy.
Vincenzo PezziDepartment of Pharmacy and Health and Nutritional Science, University of Calabria, Cosenza, Italy.
University of Calabria · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The estrogen-related receptors (ERRs) are important members of nuclear receptors which contain three isoforms (α, β, and γ). ERRα is the best-characterized isoform expressed mainly in high-energy demanding tissues where it preferentially works in association with the peroxisome proliferator-activated receptor-γ co-activator 1α (PGC-1α) and PGC-1β. ERRα together with its cofactors modulates cellular metabolism, supports the growth of rapidly dividing cells, directs metabolic programs required for cell differentiation and maintains cellular energy homeostasis in differentiated cells. In cancer cells, the functional association between ERRα and PGC-1s is further influenced by oncogenic signals and induces metabolic programs favoring cell growth and proliferation as well as tumor progression. Recently, cholesterol has been identified as a natural ERRα ligand using a combined biochemical strategy. This new finding highlighted some important physiological aspects related to the use of cholesterol-lowering drugs such as statins and bisphosphonates. Even more meaningful is the link between increased cholesterol levels and certain cancer phenotypes characterized by an overexpressed ERRα such as mammary, prostatic, and colorectal cancers, where the metabolic adaptation affects many cancer processes. Moreover, high-energy demanding cancer-related processes are strictly related to the cross-talk between tumor cells and some key players of tumor microenvironment, such as tumor-associated macrophage that fuels cancer progression. Some evidence suggests that high cholesterol content and ERRα activity favor the inflammatory environment by the production of different cytokines. In this review, starting from the most recent observations on the physiological role of the new signaling activated by the natural ligand of ERRα, we propose a new hypothesis on the suitability to control cholesterol levels as a chance in modulating ERRα activity in those tumors in which its expression and activity are increased.

Indexed as

adrenocortical carcinoma (ACC)breast and prostate cancercancer metabolismcholesterolcolonrectal cancerERRαIL-8

Identifiers

PMID30254608
PMCPMC6141749
OpenAlexW2890986230

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.